In addition to delivery of the ASO to the brain, targeting ATXN1 using RNA therapy faces another challenge, as a complete loss of ATXN1 may contribute to Alzheimer’s disease by increasing the transcription of BACE1, which encodes for the ß-secretase enzyme [25,76]. This evidence concerns the gene ATXN1 and early-onset autosomal dominant Alzheimer disease.